{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T19:37:11Z","timestamp":1776627431993,"version":"3.51.2"},"posted":{"date-parts":[[2026]]},"group-title":"SSRN","reference-count":29,"publisher":"Elsevier BV","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>\"Most Favored Nation\" drug pricing restricts patient access in reference countries even when patients face no out-of-pocket costs. We show that manufacturers narrow covered patient populations to raise measured therapeutic benefit and the benchmark price, operating through coverage determination rather than cost-sharing. Calibrating to U.S.-European price differentials, MFN pricing yields 7.1% higher global therapeutic benefit but 17.8% lower manufacturer revenue. If the reference country renegotiates its pricing rule, both therapeutic benefit and revenue increase-but the reference country's health plan bears most of the cost.<\/jats:p>","DOI":"10.2139\/ssrn.6373278","type":"posted-content","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T13:32:03Z","timestamp":1774013523000},"source":"Crossref","is-referenced-by-count":0,"title":["On the Long-Run Effects of \"Most Favored Nation\" Drug Pricing"],"prefix":"10.2139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0881-4928","authenticated-orcid":true,"given":"Pedro Lu\u00eds Oliveira Martins Pita","family":"Barros","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5455-7408","authenticated-orcid":true,"given":"Giovanni","family":"Righetti","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6396-7348","authenticated-orcid":true,"given":"Lu\u00eds","family":"S\u00e1","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"34534","key":"ref1","article-title":"Trials avoid high risk patients and underestimate drug harms","author":"J Abaluck","year":"2025"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1056\/NEJMp1705035","article-title":"The economics of indication-based drug pricing","volume":"377","author":"A Chandra","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"ref3","article-title":"What is the recommended level of patient access? An analysis of NICE's optimised decisions from","author":"B Darrow","year":"2015","journal-title":"Office of Health Economics. Retrieved from"},{"key":"ref4","author":"P Dubois","year":"2025","journal-title":"Pharmaceutical regulation and incentives for innovation in an international perspective"},{"key":"ref5","author":"P Dubois","year":"2022","journal-title":"Bargaining and international reference pricing in the pharmaceutical industry"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1257\/aer.20140202","article-title":"Identifying industry margins with price constraints: Structural estimation on pharmaceuticals","volume":"108","author":"P Dubois","year":"2018","journal-title":"American Economic Review"},{"key":"ref7","first-page":"90","article-title":"Delivering most-favored-nation prescription drug pricing to american patients","year":"2025","journal-title":"Executive Order 14297"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.2139\/ssrn.5381635","article-title":"Pricing without borders: Spillovers of external reference pricing in pharmaceutical regulation","author":"S Gamba","year":"2025"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/hec.1630","article-title":"External referencing and pharmaceutical price negotiation","volume":"20","author":"B Garcia Mari\ufffdoso","year":"2011","journal-title":"Health Economics"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1257\/jep.20251438","article-title":"Economic markets and pharmaceutical innovation","volume":"39","author":"C Garthwaite","year":"2025","journal-title":"Journal of Economic Perspectives"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jinteco.2017.08.008","article-title":"International effects of national regulations: External reference pricing and price controls","volume":"109","author":"D Geng","year":"2017","journal-title":"Journal of International Economics"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhealeco.2020.102315","article-title":"Optimal price regulations in international pharmaceutical markets with generic competition","volume":"71","author":"D Geng","year":"2020","journal-title":"Journal of Health Economics"},{"issue":"9","key":"ref13","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2025.12324","article-title":"Lowering drug prices in the US-look within, not abroad","volume":"334","author":"S Gondi","year":"2025","journal-title":"JAMA"},{"issue":"9","key":"ref14","article-title":"Policy options for the drug pricing conundrum","volume":"122","author":"K Ho","year":"2025","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"9","key":"ref15","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/jama.2025.9398","article-title":"Challenges in delivering Most-Favored-Nation pricing for prescription drugs in the US","volume":"334","author":"T J Hwang","year":"2025","journal-title":"JAMA"},{"key":"ref16","author":"K","year":"2025","journal-title":"Bristol myers plans UK launch of schizophrenia drug Cobenfy, matching US price"},{"key":"ref17","article-title":"Experts mixed on how Most-Favored-Nation drug pricing would affect prices, access, and innovation","author":"P Kakani","year":"2026","journal-title":"Health Affairs Forefront"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","DOI":"10.1007\/s10198-019-01116-4","article-title":"Does external reference pricing deliver what it promises? Evidence on its impact at national level","volume":"21","author":"P Kanavos","year":"2019","journal-title":"The European Journal of Health Economics"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1162\/rest.89.1.88","article-title":"Pharmaceutical price controls and entry strategies","volume":"89","author":"M K Kyle","year":"2007","journal-title":"The Review of Economics and Statistics"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1257\/jep.20241418","article-title":"Lessons for the United States from pharmaceutical regulation abroad","volume":"39","author":"M K Kyle","year":"2025","journal-title":"Journal of Economic Perspectives"},{"issue":"2","key":"ref21","first-page":"345","article-title":"Reference pricing as a deterrent to entry: Evidence from the European pharmaceutical market","volume":"15","author":"L Maini","year":"2023","journal-title":"American Economic Journal: Microeconomics"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1377\/hlthaff.2026.00115","article-title":"Most Favored Nation' policies and value-based drug pricing: A European view","volume":"45","author":"F Megerlin","year":"2026","journal-title":"Health Affairs"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1377\/hlthaff.2026.00184","article-title":"Most Favored Nation' drug pricing: An idea to what end?","volume":"45","author":"A W Mulcahy","year":"2026","journal-title":"Health Affairs"},{"key":"ref24","author":"A W Mulcahy","year":"2024","journal-title":"International prescription drug price comparisons: Estimates using 2022 data"},{"key":"ref25","article-title":"Most Favored Nation' policy is an unreasonable answer to a reasonable question","author":"J C Robinson","year":"2025","journal-title":"Health Affairs Forefront"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1377\/hlthaff.2025.01127","article-title":"Most Favored Nation' drug pricing is an idea whose time has come","volume":"45","author":"J C Robinson","year":"2026","journal-title":"Health Affairs"},{"issue":"49","key":"ref27","doi-asserted-by":"crossref","DOI":"10.3310\/hta8490","article-title":"Generalisability in economic evaluation studies in healthcare: A review and case studies","volume":"8","author":"M J Sculpher","year":"2004","journal-title":"Health Technology Assessment"},{"key":"ref28","author":"U K Government","year":"2025"},{"key":"ref29","journal-title":"Landmark UK-US pharmaceuticals deal to safeguard medicines access and drive vital investment for UK patients and businesses"}],"container-title":[],"original-title":[],"deposited":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T18:40:08Z","timestamp":1776624008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ssrn.com\/abstract=6373278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":29,"URL":"https:\/\/doi.org\/10.2139\/ssrn.6373278","relation":{},"subject":[],"published":{"date-parts":[[2026]]},"subtype":"preprint"}}